Unlock the Editor’s Digest without spending a dime
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly e-newsletter.
The Swedish biotech behind a groundbreaking Alzheimer’s remedy is in talks with companions for its new expertise that enables medication to cross the notoriously difficult blood-brain barrier.
BioArctic signed the primary deal for its “mind transporter” with Bristol Myers Squibb late final 12 months. The deal is price as much as $1.4bn and permits the US drugmaker to start out trials utilizing the expertise to ship one other Alzheimer’s drug.
The biotech, which created the Alzheimer’s medicine Leqembi that’s now offered by Biogen and Eisai, is in talks with a number of different massive pharmaceutical corporations to license the transporter, hoping it’ll make medication for different neurological circumstances extra profitable.
Gunilla Osswald, BioArctic chief government, stated this 12 months was a “new period” for the corporate, because it invests in its personal drug pipeline and has “lots of curiosity from Massive Pharma in our mind transporter expertise”.
Leqembi was the first drug that slowed the development of Alzheimer’s, the place different remedies might solely assist cut back signs. It was found by BioArctic’s founder Lars Lannfelt after a research of the brains of individuals with Alzheimer’s in a distant Arctic neighborhood.
Getting medication throughout the barrier into the mind has been one of many hardest issues for treating neurological circumstances. Per-Ola Freskgård, BioArctic’s vice-president of science and expertise who joined the corporate from Swiss pharmaceutical firm Roche, stated it had been a “very very massive subject within the trade”.
BioArctic’s expertise takes benefit of the biochemical course of for transporting iron into the mind to ship medication. To date, it has proof that it dramatically will increase the supply of antibody remedies into the brains of animals, however it must be examined in people.
Within the take care of Bristol Myers Squibb, BioArctic licensed each the mind transporter and a possible Alzheimer’s remedy, which is able to in all probability be in scientific trials within the subsequent two years.
In different partnerships, drugmakers are contemplating whether or not they can use the BioArctic expertise to revive older medication that had issue getting into the mind in any respect, or which brought about unacceptable unwanted effects due to the excessive dose required to get them throughout the barrier.
Roche and US biotech Denali Therapeutics are amongst these engaged on blood-brain transport applied sciences.
Osswald stated that BioArctic was extra financially steady, citing rising royalties from Leqembi. The drug is now accepted in 10 markets, although not but in Europe.
BioArctic reported its fourth-quarter earnings this month. Internet revenues have been SKr101.2.mn ($9.37mn), up from SKr11mn in the identical interval the 12 months earlier than. Its working loss narrowed to SKr53.5mn previously three months of 2024, in contrast with a lack of SKr78.1mn the earlier 12 months. Shares within the firm, which is listed in Sweden, have risen greater than 10 per cent previously 12 months.
